# Cognition Therapeutics (CGTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CGTX
## Company Profile
- Ticker: CGTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 1.04 USD
- Market cap: 120822320.25000001 USD
- Last updated: 2026-08-12
## Business Overview
### Neurodegenerative-Disease Development
Cognition Therapeutics develops small-molecule therapies for neurodegenerative disorders. Its work focuses on synaptic dysfunction and toxic protein biology associated with dementia.
### Zervimesine
Zervimesine is an oral sigma-2 receptor modulator being studied in dementia with Lewy bodies and Alzheimer's disease. The candidate is intended to protect neuronal function by regulating cellular pathways involved in protein trafficking and stress.
### Dual Clinical Strategy
The company is pursuing a registrational path in dementia with Lewy bodies psychosis while continuing a large Phase 2 program in mild cognitive impairment and early Alzheimer's disease.
## Why The Stock Is Moving

As of Aug 12, 2026, CGTX closed up 1.96% at $1.04. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA meeting in May 2026 to inform registrational plans for zervimesine in dementia with Lewy bodies psychosis.
- Topline results from the Phase 2 START study of zervimesine in 2027.

## Recent News
- 2026-08-06 20:15 EST — [Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update](https://biopharmsignal.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2026-and-dd1f3bfc) — Source: Cognition Therapeutics
- 2026-07-13 11:30 EST — [Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit](https://biopharmsignal.com/news/CGTX/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-4d2d423c) — Source: Cognition Therapeutics
- 2026-06-24 11:30 EST — [Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes](https://biopharmsignal.com/news/CGTX/cognition-therapeutics-aligns-on-key-aspects-of-pivotal-study-for-zervimesine-ct-28fb1908) — Source: Cognition Therapeutics
- 2026-06-16 11:30 EST — [Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045](https://biopharmsignal.com/news/CGTX/cognition-therapeutics-announces-new-composition-of-matter-patent-extending-pate-502b8861) — Source: Cognition Therapeutics
- 2026-06-01 11:30 EST — [Cognition Therapeutics Participating in Upcoming Investor Conferences](https://biopharmsignal.com/news/CGTX/cognition-therapeutics-participating-in-upcoming-investor-conferences-24f55c3d) — Source: Cognition Therapeutics